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 xii 
PB probability of benefit from the treatment 
PB|I conditional probability for benefit without injury 
PI probability of treatment induced injury 
r radius (general) 
r0 initial rectal radius 
x random deviate from Gaussian distribution describing organ position 
rdef radius of deformed rectal wall 
rin inner rectal wall radius 
s parameter from Kallman s-model 
S surviving fraction 
T TERMA (see abbreviations) 
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x position along LR axis (mm). 
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㬰 gradient of dose response function 
㥀 deviation or shift (of dose distribution) (mm). 
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㭠 random deviate sampled from Gaussian distribution 
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㲐 a weighting factor 
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S standard deviation between patient variables (systematic error) 
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a parameter of the Linear Quadratic model for cell killing (Gy-1) 
as hyper sensitive cell sensitive at low dose (Gy-1) 
b parameter of the Linear Quadratic model for cell killing (Gy-2) 
r clonogen density (cm-3) 
s standard deviation in random parameter (general) 
sOM standard deivation in interfraction (random) organ motion  
sp standard deviation describing the production of penumbra  
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sTD standard deviation of treatment delivery (random) errors (i.e. interfraction setup 
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Uncertainties are inevitably part of the radiotherapy process. Uncertainty in the dose 
deposited in the tumour exists due to organ motion, patient positioning errors, fluctuations 
in machine output, delineation of regions of interest, the modality of imaging used, and 
treatment planning algorithm assumptions among others; there is uncertainty in the dose 
required to eradicate a tumour due to interpatient variations in patient-specific variables 
such as their sensitivity to radiation; and there is uncertainty in the dose-volume restraints 
that limit dose to normal tissue. 
This thesis involves three major streams of research including investigation of the actual 
dose delivered to target and normal tissue, the effect of dose uncertainty on radiobiological 
indices, and techniques to display the dose uncertainty in a treatment planning system. All 
of the analyses are performed with the dose distribution from a four-field box treatment 
using 6 MV photons. The treatment fields include uniform margins between the clinical 
target volume and planning target volume of 0.5 cm, 1.0 cm, and 1.5 cm. The major work 
is preceded by a thorough literature review on the size of setup and organ motion errors for 
various organs and setup techniques used in radiotherapy. 
A Monte Carlo (MC) code was written to simulate both the treatment planning and 
delivery phases of the radiotherapy treatment. Using MC, the mean and the variation in 
treatment dose are calculated for both an individual patient and across a population of 
patients. In particular, the possible discrepancy in tumour position located from a single 
CT scan and the magnitude of reduction in dose variation following multiple CT scans is 
investigated. A novel convolution kernel to include multiple pretreatment CT scans in the 
calculation of mean treatment dose is derived. Variations in dose deposited to prostate and 
rectal wall are assessed for each of the margins and for various magnitudes of systematic 
and random error, and penumbra gradients.  
The linear quadratic model is used to calculate prostate Tumour Control Probability (TCP) 
incorporating an actual (modelled) delivered prostate dose. The Kallman s-model is used to 
calculate the normal tissue complication probability (NTCP), incorporating actual 
 xx 
(modelled) fraction dose in the deforming rectal wall. The impact of each treatment 
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